Tengye Venture Capital
腾业创投
elsewhere's corpus does not cover Tengye Venture Capital as a subject. The retrieved material only mentions it as a near-name match (cosine similarity 0.62) to Tongge Venture Capital, with no dedicated information about Tengye itself.
AI-generated — may contain errors, please verify.
Tengye Venture CapitalFund
腾业创投
No graph yet
Mentioned in 3 articles
Coverage
MaKe | MaHui Member CytoBridge Bio Closes Nearly RMB 200 Million Series B Round; Source Code Capital Led Pre-B Round
Source Code Capital Portfolio | Nutshell Therapeutics Announces $40 Million Series A+ Round, Existing Shareholder Source Code Capital Continues to Increase Stake
Advance the conformation-based drug discovery platform and innovative pipeline across all fronts
Allosteric drug discovery company Nutshell Therapeutics has raised $20 million in a Series A round led by Source Code Capital.
Currently the only platform-type allosteric drug discovery company in China driven by computational methods
